Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.
about
The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model dataImmune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected miceA mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.EVM005: an ectromelia-encoded protein with dual roles in NF-κB inhibition and virulenceImpact of distinct poxvirus infections on the specificities and functionalities of CD4+ T cell responsesRapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.Roles of vaccinia virus genes E3L and K3L and host genes PKR and RNase L during intratracheal infection of C57BL/6 mice.Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.Smallpox vaccines: targets of protective immunity.Use of a recombinant vaccinia virus expressing interferon gamma for post-exposure protection against vaccinia and ectromelia virusesPostchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus.Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics.A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.Loss of cytoskeletal transport during egress critically attenuates ectromelia virus infection in vivo.Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infectionActive vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpoxThe new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks.Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.Animal models of orthopoxvirus infection.Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses.Highlights in antiviral drug research: antivirals at the horizon.Ectromelia virus accumulates less double-stranded RNA compared to vaccinia virus in BS-C-1 cells.Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.Evaluation of Taterapox Virus in Small Animals.Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity.The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak.
P2860
Q26996686-610FB32B-365F-4892-B31E-B4B4236DD843Q28748570-55585351-CD5E-44CB-BF10-D3DB7E7149A6Q33769393-40920B26-5632-4509-9477-4A5229DC74FAQ34047542-2E20FB76-30BE-4FAF-A177-50B8A258CDF4Q34059488-4489E084-8A72-4DF7-A23C-DAE0FB305446Q34262138-D39E2CB0-9AE6-4DE7-8F43-F70CC72A01B8Q34432037-51A1E571-5C7D-4CC0-9A24-8B85B49BCBEAQ34458051-F1A8BD8B-3DA2-453F-B32F-868FBD23C515Q34483696-F82A356B-F36D-4A3E-AED6-FB26F05B87CBQ34780607-84BE969C-3932-45DF-8435-AAAE5DBBB782Q35023470-5E7E848C-B68E-41CB-86A6-D9443F787D8EQ35110971-35959ADD-61BA-4CB6-A392-1628B9BBB6F2Q35261304-58BFB335-FE3F-40B8-9685-F1E82DF7ADF1Q36130201-A717BC9C-EA86-4A56-BF7B-D3D7EF5B0314Q36155569-8FD619B8-9D12-4CD2-AAED-593B6BE3283DQ36163097-E3CFEA36-753E-4D65-AD04-CF0990B02E82Q37042331-02DD7F69-EAD4-4167-AA8B-9D043E68B7DCQ37043625-111D492C-1A58-4E23-8E31-7C506782D1EFQ37524022-EEED600E-552F-41F4-8B8A-FFBBFEAD4493Q37593480-D37AFC1B-E775-437A-BC28-F54081DEA100Q37777545-48815BEE-A6BC-403B-8C07-E303720E6F7EQ37828538-ECDF4DAA-FBE9-4528-8038-AFCB62FAD23CQ38007145-165D2A67-BAEC-4808-B6CC-BBC464946E86Q38699834-5F9E0F07-4A54-49EC-8A74-3F81ADCB255FQ38957078-122BD924-E521-417B-9E06-268D7BD56564Q40099794-20B1C0EB-9AAB-4239-B720-27FF180360F1Q41822355-02C0EFD6-88D2-4FB8-A650-A311A0797CB7Q47162853-29168A2B-1847-4F32-A665-A02661A67787
P2860
Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Mousepox in the C57BL/6 strain ...... ating anti-poxvirus therapies.
@ast
Mousepox in the C57BL/6 strain ...... ating anti-poxvirus therapies.
@en
Mousepox in the C57BL/6 strain ...... ating anti-poxvirus therapies.
@nl
type
label
Mousepox in the C57BL/6 strain ...... ating anti-poxvirus therapies.
@ast
Mousepox in the C57BL/6 strain ...... ating anti-poxvirus therapies.
@en
Mousepox in the C57BL/6 strain ...... ating anti-poxvirus therapies.
@nl
prefLabel
Mousepox in the C57BL/6 strain ...... ating anti-poxvirus therapies.
@ast
Mousepox in the C57BL/6 strain ...... ating anti-poxvirus therapies.
@en
Mousepox in the C57BL/6 strain ...... ating anti-poxvirus therapies.
@nl
P2093
P2860
P1433
P1476
Mousepox in the C57BL/6 strain ...... ating anti-poxvirus therapies.
@en
P2093
Akbar M Siddiqui
Alice Robertson
Christina Oberle
Ed Hembrador
George Painter
R Mark Buller
Randall Lanier
Scott Parker
P2860
P356
10.1016/J.VIROL.2008.11.015
P407
P577
2008-12-18T00:00:00Z